Amneal Pharmaceuticals (AMRX) announced the U.S. launch of Boruzu, a new presentation of bortezomib for ready-to-use subcutaneous administration or intravenous administration. This new ready-to-use oncology product reduces the compounding preparation steps typically required with administration.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX:
- Amneal Pharmaceuticals (AMRX) Stock Soars 45% on Success of New Parkinson’s Treatment
- Amneal Pharmaceuticals BLA submissions for denosumab biosimilars accepted by FDA
- Amneal Pharmaceuticals price target raised to $11 from $10 at Barclays
- Amneal Pharmaceuticals Reports Strong 2024 Financial Results
- Amneal Pharmaceuticals’ Earnings Call Highlights Robust Growth